Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | DRD2 | P14416 | 5/20 | 0.51 |
| ▸ | DRD3 | P35462 | 5/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | PIN1 | Q13526 | 3/20 | 0.48 |
| ▸ | PDE6D | O43924 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL484127 | 0.74 | KDM4E (0.48) | KDM4EALDH1A1SMN1; SMN2NPSR1LMNA | |
| SCHEMBL5539722 | 0.73 | KDM4E (0.69) | KDM4EALDH1A1SMN1; SMN2NPSR1LMNA | |
| SCHEMBL12324747 | 0.73 | KDM4E (0.49) | KDM4EALDH1A1SMN1; SMN2NPSR1LMNA | |
| SCHEMBL12469920 | 0.72 | KDM4E (0.45) | KDM4EALDH1A1SMN1; SMN2DRD2DRD3 | |
| SCHEMBL484301 | 0.72 | KDM4E (0.47) | KDM4EALDH1A1SMN1; SMN2DRD2DRD3 | |
| SCHEMBL12469964 | 0.71 | JAK2 (0.52) | KDM4EALDH1A1SMN1; SMN2NPSR1LMNA | |
| SCHEMBL2162731 | 0.71 | KDM4E (0.48) | KDM4EALDH1A1SMN1; SMN2NPSR1LMNA | |
| SCHEMBL12403403 | 0.71 | HPGD (0.52) | KDM4EALDH1A1SMN1; SMN2NPSR1LMNA | |
| SCHEMBL12324097 | 0.71 | KDM4E (0.73) | KDM4EALDH1A1SMN1; SMN2NPSR1LMNA | |
| SCHEMBL2163406 | 0.70 | JAK2 (0.54) | KDM4EALDH1A1SMN1; SMN2DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2411057-B1 | IMAGING AGENTS FOR DETECTING NEUROLOGICAL DISORDERS | LILLY CO ELI (US) | 2020-05-06 | — | — | EP | disclosed |
| EP-2411057-B1 | IMAGING AGENTS FOR DETECTING NEUROLOGICAL DISORDERS | LILLY CO ELI (US) | 2020-05-06 | — | — | EP | disclosed |
| EP-2550255-B1 | IMAGING AGENTS FOR DETECTING NEUROLOGICAL DISORDERS | LILLY CO ELI (US) | 2016-04-27 | — | — | EP | disclosed |
| EP-2550255-B1 | IMAGING AGENTS FOR DETECTING NEUROLOGICAL DISORDERS | LILLY CO ELI (US) | 2016-04-27 | — | — | EP | disclosed |
| US-20130302248-A1 | Imaging Agents for Detecting Neurological Disorders | LILLY CO ELI (US) | 2013-11-14 | — | — | US | disclosed |
| US-20130302248-A1 | Imaging Agents for Detecting Neurological Disorders | LILLY CO ELI (US) | 2013-11-14 | — | — | US | disclosed |
| US-20130302248-A1 | Imaging Agents for Detecting Neurological Disorders | LILLY CO ELI (US) | 2013-11-14 | — | — | US | disclosed |
| US-8491869-B2 | Imaging agents for detecting neurological disorders | ELI LILLY AND COMPANY (US) | 2013-07-23 | — | — | US | disclosed |
| EP-2411057-A2 | IMAGING AGENTS FOR DETECTING NEUROLOGICAL DISORDERS | Siemens Medical Solutions USA, Inc. (US) | 2012-02-01 | — | — | EP | disclosed |
| WO-2011119565-A1 | IMAGING AGENTS FOR DETECTING NEUROLOGICAL DISORDERS | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2011-09-29 | — | — | WO | disclosed |
| US-20110182812-A1 | Imaging Agents for Detecting Neurological Disorders | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2011-07-28 | — | — | US | disclosed |
| US-20110182812-A1 | Imaging Agents for Detecting Neurological Disorders | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2011-07-28 | — | — | US | disclosed |
| US-20110182812-A1 | Imaging Agents for Detecting Neurological Disorders | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2011-07-28 | — | — | US | disclosed |
| WO-2010111303-A2 | IMAGING AGENTS FOR DETECTING NEUROLOGICAL DISORDERS | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2010-09-30 | — | — | WO | disclosed |
| WO-2010111303-A2 | IMAGING AGENTS FOR DETECTING NEUROLOGICAL DISORDERS | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2010-09-30 | — | — | WO | disclosed |
| US-20100239496-A1 | Imaging agents for detecting neurological disorders | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| US-20100239496-A1 | Imaging agents for detecting neurological disorders | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| US-20100239496-A1 | Imaging agents for detecting neurological disorders | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130302248-A1 | Imaging Agents for Detecting Neurological Disorders | MAPT, APP, PSEN1 | KDM4E 4835/4885ALDH1A1 3291/4885SMN1; SMN2 39/4885 |
| US-20110182812-A1 | Imaging Agents for Detecting Neurological Disorders | MAPT, APP, PSEN1 | KDM4E 4835/4885ALDH1A1 3926/4885SMN1; SMN2 26/4885 |
| US-20100239496-A1 | Imaging agents for detecting neurological disorders | MAPT, APP, PSEN1 | KDM4E 4835/4885ALDH1A1 3291/4885SMN1; SMN2 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.